Blog | HemaCare

Scientists examined the peripheral blood mononuclear cell (PBMC) profiles of patients with and without psoriasis, including those that both responded to classic treatments and didn’t respond. They then analyzed the profile of those immune cell types. Here are the results of that study.

There are often differences among patient populations for a given disease in how effective a treatment provides medical relief. An important part of personalized medicine is identifying patients that are not likely to respond to a treatment regimen for a specific disease or condition. Doing this can limit the loss of time and resources in using ineffective treatments and can allow the use of personalized treatments in these populations.

A new year brings opportunities to reflect and make decisions to produce more success and happiness. These include New Year resolutions about stopping unhealthy habits and replacing with new healthy ones. Whether the goal is to eat more spinach or spend less time playing games on android phones, many will embark on changes aimed to reach health goals. There are new and emerging therapies that can help many who are struggling with medical issues to reach their health goals for the New Year. Developments such as in immunotherapy are changing the way medicine is practiced. It also provides new approaches that help our natural defense mechanisms lead us to healthier states.

Depleting B cells improves outcomes for multiple sclerosis patients, but what is the underlying biology? Peripheral blood from HemaCare helped provide answers.

Multiple sclerosis is a disease in which the protective myelin coat of nerve cells in the brain and spinal cord become damaged. Consequently, any function related to the central nervous system can be adversely affected, but the most common symptoms are severe fatigue, visual problems, altered sensitivity, and reduced mobility. The root cause of multiple sclerosis is still unknown, but the research community has learned that it is an abnormal immune-mediated response that attacks the myelin coating.

Scientists are exploring localized treatment in follicular lymphoma (FL) using dendritic cells that could have long-range benefits on all FL lesions.

Although glatiramer acetate has been around for about 20 years, we still do not have the full picture of its mode of action, especially on B cells.